A Phase 3 interventional study of Fingolimod 1.25 mg and Fingolimod 0.5 mg in Multiple Sclerosis, sponsored by Novartis. Completed at 170 sites in 18 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2017-09-21.
Sponsored by Novartis · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies testing fingolimod in Multiple Sclerosis — 2 open to participants now, 4 under way, 3 of them phase 3. fingolimod · Multiple Sclerosis.
Among the 34 studies testing fingolimod in Multiple Sclerosis, this one is the 4th largest by enrollment, is one of 3 that started in 2006, is one of 12 in phase 3, and was the 3rd registered.
3,271 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.
Browse Multiple Sclerosis studies →2 of the 34 studies testing fingolimod in Multiple Sclerosis are open now, in 3 countries. Recruiting first, the newest first:
TG Therapeutics, Inc. · Sites in United States, Poland, Slovakia
Ages 10–17
Biogen
Ages 10–17
By country, each count listing its studies:
fingolimod: first FDA approval 2010 (GILENYA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 433 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 13 · Phase 4 17
First in 2003; this study’s year is marked. 3 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,292 is above the median of 50 across 2,207 interventional studies indexed under Multiple Sclerosis.
Median enrollment 167 across the 34 interventional studies. Of the 28 that completed or were terminated, 23 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 34 have an industry lead sponsor. The 6 most frequent:
Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.
106 studies in Multiple Sclerosis by Novartis: 9 open now, 24 under way, 6 of them phase 3. Of 78 finished, 45 (58%) have results posted.
Among the 106 studies in Multiple Sclerosis by Novartis, this one is the 5th largest by enrollment of the 64 interventional ones that give a count, is one of 3 that started in 2006, is one of 23 in phase 3, and was the 3rd registered.
Novartis’s Multiple Sclerosis studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 34 studies testing fingolimod in Multiple Sclerosis, from their registry updates:
Among Novartis’s 106 in Multiple Sclerosis:
This tab as a report to print or save as PDF → With an account.
This study assessed the safety, tolerability, and efficacy of 2 doses of oral fingolimod versus interferon β-1a to reduce the frequency of relapses in patients with relapsing-remitting multiple sclerosis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria applied to the study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Fingolimod 1.25 mg
Drug: Fingolimod 0.5 mg
Drug: Interferon β-1a 30 µg
Core: Patients self-administered fingolimod 1.25 mg capsules orally once daily. In addition, they self-administered an interferon β-1a placebo intramuscular (im) injection once weekly. Extension: Patients self-administered fingolimod 1.25 mg capsules orally once daily until switched to 0.5 mg capsules upon study protocol amendment.
Also known as: FTY720
Core: Patients self-administered fingolimod 0.5 mg capsules orally once daily. In addition, they self-administered an interferon β-1a placebo intramuscular (im) injection once weekly. Extension: Patients self-administered fingolimod 0.5 mg capsules orally once daily.
Also known as: FTY720
Core: Patients self-administered interferon β-1a 30 μg in an intramuscular (im) injection once weekly. In addition, they self-administered a fingolimod placebo capsule orally once daily. Extension: Patients self-administered either fingolimod 1.25 mg or 0.5 mg capsules orally once daily until switched to 0.5 mg capsules upon study protocol amendment.
Estimated Annualized Aggregate Relapse Rate (ARR) in the Core Phase of the Study
The ARR is defined as the number of confirmed relapses in a year. A relapse is defined as the appearance of a new or worsening of a previously stable or improving pre existing neurological abnormality, separated by at least 30 days from onset of a preceding relapse. The abnormality must be present for at least 24 hours and occur in the absence of fever or infection. The annualized ARR for each treatment group was calculated using negative binomial regression adjusted by treatment, country, number of relapses in the previous 2 years, and the baseline Expanded Disability Status Scale score.
Time frame: Baseline to Month 12
Number of New or Newly Enlarged T2 Lesions in Comparison With Baseline in the Core Phase of the Study
The number of new or newly enlarged T2 lesions in comparison to baseline was assessed with T2-weighted magnetic resonance image (MRI) scans. A T2-weighted MRI scan utilizes particular values of the echo time (TE) and the repetition time (TR) parameters of image acquisition. Inflammation and tissue damage are seen as bright areas in T2 images and are often referred to as T2 lesions. T2-weighted MRI scans are a sensitive way to evaluate the brain for demyelinating diseases, such as multiple sclerosis.
Time frame: Baseline to Month 12
Percentage of Participants Free of 3-month Disability Progression Assessed With the Expanded Disability Status Scale (EDSS) at the End of the Core Phase of the Study
The EDSS is a scale for assessing disability in 8 functional systems (visual, brain stem, pyramidal, cerebellar, sensory, bowel \& bladder, cerebral, other functions). An overall score ranging from 0 (normal) to 10 (death due to MS) is calculated. Disability progression was determined by the EDSS score based on the following criteria: One point increase from baseline in patients with baseline EDSS score from 0 to 5.0; or half a point increase in patients with baseline EDSS score of 5.5 or above. Percent of patients free of disability progression was calculated using the Kaplan-Meier method.
Time frame: Baseline to Month 12
Estimated Annualized Aggregate Relapse Rate (ARR) in the Core and Extension Phases of the Study
The ARR is defined as the number of confirmed relapses in a year. A relapse is defined as the appearance of a new or worsening of a previously stable or improving pre existing neurological abnormality, separated by at least 30 days from onset of a preceding relapse. The abnormality must be present for at least 24 hours and occur in the absence of fever or infection. The annualized ARR for each treatment group was calculated using negative binomial regression adjusted by treatment, country, number of relapses in the previous 2 years, and the baseline Expanded Disability Status Scale score.
Time frame: Month 0 to end of study (up to approximately 4.5 years)
Number of New or Newly Enlarged T2 Lesions in the Extension Phase of the Study
The number of new or newly enlarged T2 lesions in comparison to baseline was assessed with T2-weighted magnetic resonance image (MRI) scans. A T2-weighted MRI scan utilizes particular values of the echo time (TE) and the repetition time (TR) parameters of image acquisition. Inflammation and tissue damage are seen as bright areas in T2 images and are often referred to as T2 lesions. T2-weighted MRI scans are a sensitive way to evaluate the brain for demyelinating diseases, such as multiple sclerosis.
Time frame: Month 12 to end of study (up to approximately 3.5 years)
Percentage of Participants Free of 3-month and 6-month Disability Progression Assessed With the Expanded Disability Status Scale (EDSS) at the End of the Extension Phase of the Study
The EDSS is a scale for assessing disability in 8 functional systems (visual, brain stem, pyramidal, cerebellar, sensory, bowel \& bladder, cerebral, other functions). An overall score ranging from 0 (normal) to 10 (death due to MS) is calculated. Disability progression was determined by the EDSS score based on the following criteria: One point increase from baseline in patients with baseline EDSS score from 0 to 5.0; or half a point increase in patients with baseline EDSS score of 5.5 or above. Percent of patients free of disability progression was calculated using the Kaplan-Meier method.
Time frame: Baseline to end of study (up to approximately 4.5 years)
Patients randomized in the Core Phase (CP) to receive 0.5 mg or 1.25 mg fingolimod received the same dose in the Extension Phase (EP). Patients randomized to receive interferon-β-1a in the CP were re-randomized to receive either 0.5 mg or 1.25 mg fingolimod in a 1:1 ratio in the EP. Upon protocol amendment, all patients received 0.5 mg fingolimod.
| Milestone | Fingolimod 1.25 mg | Fingolimod 0.5 mg | Interferon β-1a 30 µg | Interferon β-1a/Fingolimod 1.25 mg | Interferon β-1a/Fingolimod 0.5 mg |
|---|---|---|---|---|---|
| Started | 426 | 431 | 435 | 0 | 0 |
| Completed | 369 | 398 | 386 | 0 | 0 |
| Not completed | 57 | 33 | 49 | 0 | 0 |
| Withdrew: Adverse event | 26 | 9 | 9 | 0 | 0 |
| Withdrew: Withdrawal by subject | 11 | 9 | 16 | 0 | 0 |
| Withdrew: Administrative problems | 6 | 2 | 7 | 0 | 0 |
| Withdrew: Lack of efficacy | 3 | 3 | 7 | 0 | 0 |
| Withdrew: Abnormal laboratory value(s) | 4 | 6 | 1 | 0 | 0 |
| Withdrew: Abnormal test procedure result(s) | 4 | 3 | 3 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 1 | 4 | 0 | 0 |
| Withdrew: Death | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 2 | 0 | 0 |
| Milestone | Fingolimod 1.25 mg | Fingolimod 0.5 mg | Interferon β-1a 30 µg | Interferon β-1a/Fingolimod 1.25 mg | Interferon β-1a/Fingolimod 0.5 mg |
|---|---|---|---|---|---|
| Started | 330 | 357 | 0 | 176 | 167 |
| Received study drug | 330 | 356 | 0 | 174 | 167 |
| Completed | 245 | 281 | 0 | 123 | 123 |
| Not completed | 85 | 76 | 0 | 53 | 44 |
| Withdrew: Subject did not receive study drug | 0 | 1 | 0 | 2 | 0 |
| Withdrew: Subject withdrew consent | 26 | 31 | 0 | 12 | 15 |
| Withdrew: Adverse event | 21 | 22 | 0 | 19 | 7 |
| Withdrew: Abnormal laboratory value(s) | 14 | 13 | 0 | 13 | 4 |
| Withdrew: Unsatisfactory therapeutic effect | 13 | 7 | 0 | 4 | 9 |
| Withdrew: Lost to follow-up | 1 | 1 | 0 | 2 | 3 |
| Withdrew: Subject no longer requires study drug | 4 | 0 | 0 | 0 | 2 |
| Withdrew: Administrative problems | 3 | 0 | 0 | 1 | 1 |
| Withdrew: Abnormal test procedure result(s) | 0 | 1 | 0 | 0 | 2 |
| Withdrew: Protocol violation | 3 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 1 |
The ARR is defined as the number of confirmed relapses in a year. A relapse is defined as the appearance of a new or worsening of a previously stable or improving pre existing neurological abnormality, separated by at least 30 days from onset of a preceding relapse. The abnormality must be present for at least 24 hours and occur in the absence of fever or infection. The annualized ARR for each treatment group was calculated using negative binomial regression adjusted by treatment, country, number of relapses in the previous 2 years, and the baseline Expanded Disability Status Scale score.
| Estimate relapses per year | Fingolimod 1.25 mg | Fingolimod 0.5 mg | Interferon β-1a µg/Fingolimod 1.25 or 0.5 mg |
|---|---|---|---|
| Estimated Annualized Aggregate Relapse Rate (ARR) in the Core Phase of the Study | 0.203 (0.157 to 0.264) | 0.161 (0.122 to 0.212) | 0.331 (0.262 to 0.417) |
The number of new or newly enlarged T2 lesions in comparison to baseline was assessed with T2-weighted magnetic resonance image (MRI) scans. A T2-weighted MRI scan utilizes particular values of the echo time (TE) and the repetition time (TR) parameters of image acquisition. Inflammation and tissue damage are seen as bright areas in T2 images and are often referred to as T2 lesions. T2-weighted MRI scans are a sensitive way to evaluate the brain for demyelinating diseases, such as multiple sclerosis.
| T2 lesions | Fingolimod 1.25 mg | Fingolimod 0.5 mg | Interferon β-1a µg/Fingolimod 1.25 or 0.5 mg |
|---|---|---|---|
| Number of New or Newly Enlarged T2 Lesions in Comparison With Baseline in the Core Phase of the Study | 1.6 ± 3.23 | 1.6 ± 3.16 | 2.6 ± 5.50 |
The EDSS is a scale for assessing disability in 8 functional systems (visual, brain stem, pyramidal, cerebellar, sensory, bowel \& bladder, cerebral, other functions). An overall score ranging from 0 (normal) to 10 (death due to MS) is calculated. Disability progression was determined by the EDSS score based on the following criteria: One point increase from baseline in patients with baseline EDSS score from 0 to 5.0; or half a point increase in patients with baseline EDSS score of 5.5 or above. Percent of patients free of disability progression was calculated using the Kaplan-Meier method.
| Percentage of participants | Fingolimod 1.25 mg | Fingolimod 0.5 mg | Interferon β-1a µg/Fingolimod 1.25 or 0.5 mg |
|---|---|---|---|
| Percentage of Participants Free of 3-month Disability Progression Assessed With the Expanded Disability Status Scale (EDSS) at the End of the Core Phase of the Study | 93.3 (90.92 to 95.77) | 94.1 (91.82 to 96.33) | 92.1 (89.45 to 94.66) |
The ARR is defined as the number of confirmed relapses in a year. A relapse is defined as the appearance of a new or worsening of a previously stable or improving pre existing neurological abnormality, separated by at least 30 days from onset of a preceding relapse. The abnormality must be present for at least 24 hours and occur in the absence of fever or infection. The annualized ARR for each treatment group was calculated using negative binomial regression adjusted by treatment, country, number of relapses in the previous 2 years, and the baseline Expanded Disability Status Scale score.
| Estimated relapses per year | Fingolimod 1.25 mg | Fingolimod 0.5 mg | Interferon β-1a µg/Fingolimod 1.25 or 0.5 mg |
|---|---|---|---|
| Month 12 to Month 24, n=330, 356, 341 | 0.156 (0.114 to 0.214) | 0.182 (0.138 to 0.242) | 0.266 (0.207 to 0.341) |
| Month 24 to Month 36, n=287, 321, 293 | 0.116 (0.079 to 0.169) | 0.110 (0.076 to 0.160) | 0.121 (0.084 to 0.176) |
| Month 36 to Month 48, n=267, 303, 271 | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
| Month 48 to end of study, n=36, 38, 29 | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
| Month 0 to end of study, n=420, 429, 431 | 0.192 (0.160 to 0.229) | 0.166 (0.139 to 0.199) | 0.271 (0.230 to 0.318) |
The number of new or newly enlarged T2 lesions in comparison to baseline was assessed with T2-weighted magnetic resonance image (MRI) scans. A T2-weighted MRI scan utilizes particular values of the echo time (TE) and the repetition time (TR) parameters of image acquisition. Inflammation and tissue damage are seen as bright areas in T2 images and are often referred to as T2 lesions. T2-weighted MRI scans are a sensitive way to evaluate the brain for demyelinating diseases, such as multiple sclerosis.
| T2 lesions | Fingolimod 1.25 mg | Fingolimod 0.5 mg | Interferon β-1a µg/Fingolimod 1.25 or 0.5 mg |
|---|---|---|---|
| Month 12 to Month 24 | 1.08 ± 2.644 | 0.87 ± 1.624 | 0.97 ± 1.923 |
| Month 24 to Month 36, n=255, 289, 258 | 1.40 ± 3.418 | 1.04 ± 4.408 | 0.72 ± 1.733 |
| Month 36 to Month 48, n=36, 34, 35 | 0.97 ± 1.682 | 0.59 ± 1.438 | 0.49 ± 1.483 |
| Last MRI scan to end of study, n=275, 309, 290 | 1.75 ± 7.248 | 0.86 ± 2.674 | 1.03 ± 4.350 |
The EDSS is a scale for assessing disability in 8 functional systems (visual, brain stem, pyramidal, cerebellar, sensory, bowel \& bladder, cerebral, other functions). An overall score ranging from 0 (normal) to 10 (death due to MS) is calculated. Disability progression was determined by the EDSS score based on the following criteria: One point increase from baseline in patients with baseline EDSS score from 0 to 5.0; or half a point increase in patients with baseline EDSS score of 5.5 or above. Percent of patients free of disability progression was calculated using the Kaplan-Meier method.
| Percentage of participants | Fingolimod 1.25 mg | Fingolimod 0.5 mg | Interferon β-1a µg/Fingolimod 1.25 or 0.5 mg |
|---|---|---|---|
| Free of 3-month progression | 67.01 (57.26 to 95.77) | 71.28 (63.69 to 78.87) | 73.40 (68.56 to 78.23) |
| Free of 6-month progression | 79.54 (75.07 to 84.00) | 79.76 (75.53 to 83.98) | 81.61 (77.39 to 85.83) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| COR FTY720 1.25 mg | — | 45/420 (10.7%) | 310/420 (73.8%) |
| COR FTY720 0.5 mg | — | 30/429 (7%) | 302/429 (70.4%) |
| COR Interferon Beta-1a | — | 25/431 (5.8%) | 359/431 (83.3%) |
| EXT FTY720 1.25 mg | — | 77/504 (15.3%) | 446/504 (88.5%) |
| EXT FTY720 0.5 mg | — | 76/523 (14.5%) | 439/523 (83.9%) |
| Event | COR FTY720 1.25 mg | COR FTY720 0.5 mg | COR Interferon Beta-1a | EXT FTY720 1.25 mg | EXT FTY720 0.5 mg |
|---|---|---|---|---|---|
| BradycardiaCardiac disorders | 8/420 | 1/429 | 0/431 | 3/504 | 1/523 |
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/420 | 2/429 | 0/431 | 4/504 | 7/523 |
| Multiple sclerosis relapseNervous system disorders | 0/420 | 1/429 | 1/431 | 4/504 | 6/523 |
| VertigoEar and labyrinth disorders | 0/420 | 0/429 | 1/431 | 4/504 | 0/523 |
| Herpes zosterInfections and infestations | 1/420 | 0/429 | 0/431 | 4/504 | 1/523 |
| CholelithiasisHepatobiliary disorders | 0/420 | 1/429 | 1/431 | 0/504 | 4/523 |
| Atrioventricular block second degreeCardiac disorders | 3/420 | 1/429 | 0/431 | 2/504 | 0/523 |
| LymphopeniaBlood and lymphatic system disorders | 1/420 | 0/429 | 0/431 | 3/504 | 1/523 |
| PneumoniaInfections and infestations | 0/420 | 0/429 | 0/431 | 3/504 | 1/523 |
| Atrioventricular block first degreeCardiac disorders | 2/420 | 1/429 | 0/431 | 1/504 | 0/523 |
| Event | COR FTY720 1.25 mg | COR FTY720 0.5 mg | COR Interferon Beta-1a | EXT FTY720 1.25 mg | EXT FTY720 0.5 mg |
|---|---|---|---|---|---|
| Influenza like illnessGeneral disorders | 15/420 | 15/429 | 158/431 | 24/504 | 18/523 |
| NasopharyngitisInfections and infestations | 93/420 | 88/429 | 88/431 | 158/504 | 162/523 |
| HeadacheNervous system disorders | 96/420 | 99/429 | 88/431 | 86/504 | 107/523 |
| LymphopeniaBlood and lymphatic system disorders | 3/420 | 1/429 | 0/431 | 108/504 | 77/523 |
| PyrexiaGeneral disorders | 14/420 | 18/429 | 76/431 | 33/504 | 30/523 |
| Upper respiratory tract infectionInfections and infestations | 36/420 | 31/429 | 27/431 | 75/504 | 59/523 |
| FatigueGeneral disorders | 60/420 | 44/429 | 45/431 | 39/504 | 40/523 |
| Lymphocyte count decreasedInvestigations | 1/420 | 2/429 | 0/431 | 72/504 | 42/523 |
| Back painMusculoskeletal and connective tissue disorders | 27/420 | 26/429 | 23/431 | 60/504 | 53/523 |
| Urinary tract infectionInfections and infestations | 24/420 | 26/429 | 21/431 | 49/504 | 58/523 |
| Age, Continuous(years) | Fingolimod 1.25 mg | Fingolimod 0.5 mg | Interferon β-1a 30 µg | Interferon β-1a/Fingolimod 1.25 mg | Interferon β-1a/Fingolimod 0.5 mg | Total |
|---|---|---|---|---|---|---|
| Mean | 35.8 ± 8.39 | 36.7 ± 8.81 | 36.0 ± 8.29 | NA ± NA | NA ± NA | 36.2 ± 8.50 |
| Age, Continuous(Years) | Fingolimod 1.25 mg | Fingolimod 0.5 mg | Interferon β-1a 30 µg | Interferon β-1a/Fingolimod 1.25 mg | Interferon β-1a/Fingolimod 0.5 mg | Total |
|---|---|---|---|---|---|---|
| Mean | 35.5 ± 8.42 | 36.5 ± 8.67 | NA ± NA | 36.1 ± 8.11 | 36.1 ± 8.59 | 36.0 ± 8.48 |
| Age, Customized(Participants) | Fingolimod 1.25 mg | Fingolimod 0.5 mg | Interferon β-1a 30 µg | Interferon β-1a/Fingolimod 1.25 mg | Interferon β-1a/Fingolimod 0.5 mg | Total |
|---|---|---|---|---|---|---|
| < 18 | 0 | 0 | 0 | NA | NA | 0 |
| 18-30 | 125 | 117 | 113 | NA | NA | 355 |
| 31-40 | 160 | 150 | 185 | NA | NA | 495 |
| 41-55 | 141 | 164 | 137 | NA | NA | 442 |
| > 55 | 0 | 0 | 0 | NA | NA | 0 |
| Age, Customized(Participants) | Fingolimod 1.25 mg | Fingolimod 0.5 mg | Interferon β-1a 30 µg | Interferon β-1a/Fingolimod 1.25 mg | Interferon β-1a/Fingolimod 0.5 mg | Total |
|---|---|---|---|---|---|---|
| < 18 | 0 | 0 | NA | 0 | 0 | 0 |
| 18-30 | 100 | 98 | NA | 39 | 48 | 285 |
| 31-40 | 122 | 127 | NA | 83 | 62 | 394 |
| 41-55 | 108 | 131 | NA | 52 | 57 | 348 |
| >55 | 0 | 0 | NA | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Fingolimod 1.25 mg | Fingolimod 0.5 mg | Interferon β-1a 30 µg | Interferon β-1a/Fingolimod 1.25 mg | Interferon β-1a/Fingolimod 0.5 mg | Total |
|---|---|---|---|---|---|---|
| Female | 293 | 282 | 295 | NA | NA | NA |
| Male | 133 | 149 | 140 | NA | NA | NA |
| Sex/Gender, Customized(Participants) | Fingolimod 1.25 mg | Fingolimod 0.5 mg | Interferon β-1a 30 µg | Interferon β-1a/Fingolimod 1.25 mg | Interferon β-1a/Fingolimod 0.5 mg | Total |
|---|---|---|---|---|---|---|
| Female | 227 | 235 | NA | 114 | 109 | 685 |
| Male | 103 | 121 | NA | 60 | 58 | 342 |
Showing the first 100 of 170 sites across 18 countries. Choose a country and city above to see the rest.
The record gives a start of May 2006, a primary completion of Jul 2011 and a completion of Jul 2011. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fingolimod